VX1 fundamentals
An in-depth look to VERTEX PHARMACEUTICALS INC operating, investing, and financing activities
VX1 free cash flow for Q1 24 is 1.12 B CHF. For 2023, VX1 free cash flow was 2.81 B CHF and operating cash flow was 2.98 B CHF.
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: CHF
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
TTM